Swiss drug maker NovImmune has begun a proof-of-concept study to evaluate NI-0801 in patients with primary biliary cirrhosis.

NI-0801 is a fully human monoclonal antibody that neutralises CXCL10 / interferon-gamma-inducible protein-10 (IP-10) chemokine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Two previous Phase I trials have demonstrated that the drug is safe and well tolerated when given to healthy volunteers.

Principal investigator David Adams said that the therapeutic approach of neutralising CXCL10 / IP-10 with NI-0801 will offer great benefits to the large and therapeutically ill-served primary biliary cirrhosis patient population.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now